Evidence map›Paper›PMID 31235278›Full record

ReviewMayo Clinic proceedings2019

Oncolytic Measles Virotherapy and Opposition to Measles Vaccination.

Stephen J Russell, Dusica Babovic-Vuksanovic, Alice Bexon, Roberto Cattaneo, David Dingli, Angela Dispenzieri, David R Deyle, Mark J Federspiel, Adele Fielding, Eva Galanis and 16 more

Open access · hybridAbstract readReview
In one paragraph

Review in Mayo Clinic proceedings, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Evolving progress in the management of malignant plasma cell disorders.Cancer treatment and research communications · 2022
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 7 institutions in 3 countries.

Stephen J RussellDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN; Division of Hematology, Mayo Clinic, Rochester, MN. Electronic address: sjr@mayo.edu.
Dusica Babovic-VuksanovicDivision of Medical Genetics, Mayo Clinic, Rochester, MN.
Alice BexonVyriad, Rochester, MN.
Roberto CattaneoDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN.
David DingliDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN; Division of Hematology, Mayo Clinic, Rochester, MN.
Angela DispenzieriDivision of Hematology, Mayo Clinic, Rochester, MN.
David R DeyleDivision of Medical Genetics, Mayo Clinic, Rochester, MN.
Mark J FederspielDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN.
Adele FieldingDepartment of Hematology, UCL Cancer Institute, London, UK.
Eva GalanisDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN; Division of Medical Oncology, Mayo Clinic, Rochester, MN.
Martha Q LacyDivision of Hematology, Mayo Clinic, Rochester, MN.
Bradley C LeibovichDepartment of Urology, Mayo Clinic, Rochester, MN.
Minetta C LiuDivision of Medical Oncology, Mayo Clinic, Rochester, MN.
Miguel Muñoz-AlíaDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN.
Tanner C MiestDepartment of Urology, Mayo Clinic, Rochester, MN.
Julian R MolinaDivision of Medical Oncology, Mayo Clinic, Rochester, MN.
Sabine MuellerDepartment of Neurology, University of California, San Francisco.
Scott H OkunoDivision of Medical Oncology, Mayo Clinic, Rochester, MN.
Nandakumar PackiriswamyDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN.
Tobias PeikertDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.
Corey RaffelDepartment of Neurology, University of California, San Francisco.
Frits Van RheeUAMS Myeloma Center, University of Arkansas for Medical Sciences, Little Rock.
Guy UngerechtsDepartment of Medical Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Paul R YoungDepartment of Urology, Mayo Clinic, Jacksonville, FL.
Yumei ZhouDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN.
Kah-Whye PengDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN.
Mayo Clinic in Arizona · USMayo Clinic · USUniversity of California, San Francisco · USCRUK Lung Cancer Centre of Excellence · GBHeidelberg University · DEMayo Clinic in Florida · USUniversity of Arkansas for Medical Sciences · US

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Peter Leif Bergsagel · 2015 to 2026
$25.5M
NCI NIH HHS P50 CA186781
6 · The paper itself

Abstract

Recent measles epidemics in US and European cities where vaccination coverage has declined are providing a harsh reminder for the need to maintain protective levels of immunity across the entire population. Vaccine uptake rates have been declining in large part because of public misinformation regarding a possible association between measles vaccination and autism for which there is no scientific basis. The purpose of this article is to address a new misinformed antivaccination argument-that measles immunity is undesirable because measles virus is protective against cancer. Having worked for many years to develop engineered measles viruses as anticancer therapies, we have concluded (1) that measles is not protective against cancer and (2) that its potential utility as a cancer therapy will be enhanced, not diminished, by prior vaccination.

Indexed as

CommunicationChildChild, PreschoolCommunicable Disease ControlEuropeFemaleHumansMaleMeaslesMeasles virusOncolytic VirotherapyPrevalenceRisk AssessmentUnited StatesVaccination

Identifiers

PMID31235278
PMCPMC6800178
OpenAlexW2950778492

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.